Status In progress
Process TAG

Timeline

Key events during the development of the guidance:

Date Update
28 December 2018 As you will be aware the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of caplacizumab within its marketing authorisation for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), in conjunction with plasma exchange and immunosuppression. Please note that following on from advice received from the company this appraisal has now been rescheduled back into the work programme. The appraisal is now anticipated to being in early August 2019.
14 June 2018 In progress, Topic referred
14 June 2018 As you will be aware the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of caplacizumab within its marketing authorisation for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), in conjunction with plasma exchange and immunosuppression. The timelines for this appraisal are still to be confirmed following a recent update from Ablynx related to Sanofi’s previously announced tender offers to acquire all of the outstanding shares (including shares represented by American Depositary Shares, warrants and convertible bonds) of Ablynx. Please refer to link for further information http://www.ablynx.com/uploads/data/files/press%20release_sanofi%20squeez%20out_14%20may%202018_eng_final.pdf NICE is monitoring the situation and will update interested parties as and when further information is available.
05 December 2017 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance